Ionis Pharmaceuticals
Ionis Pharmaceuticals, Inc.
2855 Gazelle Court
Carlsbad, CA 92010
Phone: (760) 931-9200Website: https://www.ionispharma.com/Careers: www.ionispharma.com/careers
Latest news
- FDA Approves Tryngolza (olezarsen) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome
19 December 2024 - Ionis Announces Olezarsen New Drug Application Accepted for Priority Review and Enrollment in Phase 3 sHTG Program Completed
25 June 2024 - Ionis Presents Positive Results from Phase 3 Balance Study of Olezarsen for Familial Chylomicronemia Syndrome
7 April 2024 - Ionis Receives FDA Fast Track Designation for Olezarsen in Patients with Familial Chylomicronemia Syndrome
31 January 2023 - Ionis Initiates Pivotal Phase 3 Clinical Study of Olezarsen in Patients with Severe Hypertriglyceridemia
2 November 2021
Drugs Associated with Ionis Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc. manufactures, markets and/or distributes more than 5 drugs in the United States. Medications listed here may also be marketed under different names in different countries. Non-US country and region specific information is not available on this page.
| Brand/Generic Name | Reviews | Rating |
|---|---|---|
|
Qalsody
Generic name: tofersen Drug class: miscellaneous central nervous system agents |
||
|
Spinraza
Generic name: nusinersen Drug class: miscellaneous uncategorized agents |
||
|
Tegsedi
Generic name: inotersen Drug class: miscellaneous metabolic agents |
||
|
Tryngolza
Generic name: olezarsen Drug class: miscellaneous antihyperlipidemic agents |
||
|
Wainua
Generic name: eplontersen Drug class: miscellaneous metabolic agents |
||
| For ratings, users were asked how effective they found the medicine while considering positive/adverse effects and ease of use (1 = not effective, 10 = most effective). | ||